Association between endocrine therapy and survival outcomes in estrogen receptor–low breast cancer: a systematic review and meta-analysis
The Oncologist · 06.06.2026 · 31 (7)
DOI: 10.1093/oncolo/oyag230 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, online erschienen am 10.06.2026. Verfasst von Fan Xia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, West China School of Medicine, Sichuan University, Chengdu, 610000, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Receptors, Estrogen, Antineoplastic Agents, Hormonal. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The clinical significance of endocrine therapy (ET) in patients with estrogen receptor–low (ER-low, 1%-10%) breast cancer remains uncertain. Increasing evidence suggests that these tumors differ biologically from typical hormone receptor–positive cancers, raising questions about the true benefit of ET in this subgroup.
Methods
This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to July 1, 2025. Hazard ratios (HRs) with corresponding 95% CIs for time-to-event outcomes were extracted directly or estimated from Kaplan–Meier curves when not explicitly reported. Pooled analyses were performed using random-effects models to account for between-study heterogeneity. The protocol was registered in PROSPERO (CRD420251055521).
Results
A total of 6 retrospective observational studies involving 8765 patients with estrogen receptor–low breast cancer were included. Endocrine therapy was associated with improved overall survival (OS) (HR 0.81, 95% CI 0.69-0.95; P = .01; I2 = 0%) and disease-free survival (DFS) (HR 0.64, 95% CI 0.45-0.90; P = .01; I2 = 0%).
Conclusions
Endocrine therapy was associated with improved OS and DFS in patients with estrogen receptor–low breast cancer. These findings suggest that estrogen receptor–low breast cancer should not be uniformly considered endocrine-insensitive and that routine omission of endocrine therapy should be approached cautiously. Given that the available evidence is derived from retrospective observational studies, further prospective studies are needed to identify patients most likely to benefit from endocrine therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, West China School of Medicine, Sichuan University, Chengdu, 610000, China.
- Department of Oncology, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu, 610000, China.
- Department of Oncology, Chengdu Second People's Hospital, Chengdu, 610000, China.
- Department of Respiratory and Critical Care Medicine, West China School of Medicine, Sichuan University, Chengdu, 610000, China.
- Department of Respiratory and Critical Care Medicine, Sichuan University Affiliated Chengdu Second People's Hospital, Chengdu, 610000, China.
- Department of Respiratory and Critical Care Medicine, Chengdu Second People's Hospital, Chengdu, 610000, China.
ORCID-Profile: Mei Xie
Zitieren
APA
Xia, F., Hu, X., Zhang, L., Peng, X., & Xie, M. (2026). Association between endocrine therapy and survival outcomes in estrogen receptor–low breast cancer: a systematic review and meta-analysis. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag230
Vancouver
Xia F, Hu X, Zhang L, Peng X, Xie M. Association between endocrine therapy and survival outcomes in estrogen receptor–low breast cancer: a systematic review and meta-analysis. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag230
BibTeX
@article{Xia2026,
author = {Xia, Fan and Hu, XiaoBo and Zhang, Lei and Peng, XiaoDong and Xie, Mei},
title = {Association between endocrine therapy and survival outcomes in estrogen receptor–low breast cancer: a systematic review and meta-analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {7},
doi = {10.1093/oncolo/oyag230}
}
EUVIMED